[Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Zotepine, a neuroleptic exercising a 5-HT2-antagonistic effect, was employed in a double-blind study in the treatment of schizophrenic patients with predominantly negative symptoms and was compared to haloperidol. In contrast to the patients treated with haloperidol, significant improvements were seen in the zotepine group during the observation period, according to all assessment scales that were employed. The patients of the zotepine group also developed fewer clinical side effects. The results of the study confirm previous positive impressions gained in earlier open studies with zotepine.
Arbeitsgruppe für Biologische Psychiatrie, Universität Innsbruck Osterreich.
C
C
Barnas
C H
CH
Stuppäck
C
C
Miller
C
C
Haring
B
B
Sperner-Unterweger
W W
WW
Fleischhacker
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003988:Dibenzothiepins / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D003988:Dibenzothiepins; D006220:Haloperidol; C022172:zotepine
Zotepin: Die Behandlung schizophrener Patienten mit vorherrschender Negativsymptomatik. Eine Doppelblindstudie vs. Haloperidol.